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1. Introduction 
Energy is stored in plants in form of carbohydrates, including sucrose (i.e., saccharose, a 
disaccharide) and starch (a polysaccharide). Sucrose and starch are derived from glucose, 
the product of carbon dioxide and water in photosynthesis. These carbohydrates are not 
only essential as energy supplies in food and animal feed, but in recent years have also been 
tapped as a renewable fuel energy source by the fuel ethanol industry. Some plants, like 
sugar cane or sugar beet, produce juice rich in sucrose, a mixed glucose-fructose 
disaccharide. Brewer’s yeast (Saccharomyces cerevisiae) can directly ferment sucrose into 
ethanol, whereas starch, like that found in corn or potatoes, must first be hydrolyzed, to 
glucose or fermentable glucose oligosaccharides by an enzyme (e.g., amylase) before 
fermenting into ethanol. Cellulose, structural polysaccharides in plants, is even more 
difficult to hydrolyze to glucose. To obtain fermentable sugars, cellulose-containing plant 
material is usually subjected to a physicochemical pretreatment followed by enzymatic 
hydrolysis with cellulases. Such pretreatment processes are expensive and not yet used 
commercially on a large scale.  
Because sugar and starch are major components of human food, and cellulose is the 
principal component of ruminant feed, their large-scale use in fuel alcohol production is 
already affecting food prices in the world. Brazil began producing fuel ethanol from sugar 
cane 36 years ago and in 2010 supplied enough ethanol to sell gasoline containing 25% 
ethanol throughout the country. Similarly, a large-scale, government sponsored program of 
fuel ethanol production from starch, using maize as its source, was started in the United 
States in 2007. This industry has created vast quantities of yeast byproducts; including a 
commercial-scale source of yeast extract, yeast glucose and mannose polysaccharides. Sugar 
cane juice and sugar beet juice fermentations are especially convenient for yeast collection, 
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because the post-fermentation solution does not contain solids such as non-fermentable 
residues, like those produced during corn mash fermentation.  
The yeast cell wall contains three major constituents: glucan (glucose polysaccharide), 
mannan (mannose polysaccharide) and a protein fraction. The separation of these natural 
polymers is simple and inexpensive. However, it is difficult and expensive to obtain more 
than 65% pure fractions and, therefore, these components are produced and sold at these 
low levels of purity. Their largest commercial application has been as animal feed 
nutritional supplements (see, http://www.Alltech.com).  
There are three well known types of glucose polysaccharides in yeast: poly-(1→3)(1→6)-β-
D-glucopyranose - commercial name: yeast β-D-glucan, yeast glucan; poly-(1→4)-α-D-
glucopyranose (commercial name yeast glucogen) and poly-(1→6)(1→3)(1→4)-α-D-
glucopyranose a recently “rediscovered” polysaccharide (Arvindecar & Patil, 2002) yet 
without a commercial name. The prefix “poly” informs about the polymeric nature of the 
material built of D-glucose cyclic monomers (D-glucopyranose rings) and the letter D 
informs that glucose belongs to the group of naturally occurring plant sugars with D 
stereochemistry. The letter α or β refers to the configuration of the glycosidic bonds between 
the C-1 of a nonreducing ring and the C-6 of a reducing ring or the C-1 of a nonreducing 
ring and the C-3 of a reducing ring (see Fig. 1, Lindhorst 2003). Figure 1 shows structures of 
β-D-glucopyranose isomer with a C-1 OH group in the β position (solid line) or a C-1 OH 
group in the (α) position (dotted line). Penta-(1→6)(1→3)-β-D-glucopyranose drawing 
shows the location of all OH groups, glycosidic bonds and glucopyranose rings within the 
structure. (The hydrogen atoms attached to carbon atoms are not shown.)  
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Figure 1.  
Solving polysaccharide structure is not simple. At first, a sample needs to be homogenous 
and 98-99% pure. Different separation techniques (i.e., size exclusion chromatography, 
affinity (lectin) chromatography and in some cases high performance liquid 
chromatography (HPLC) are suitable for the purification of water or solvent soluble 
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samples. Spectroscopic methods, such as 1H and 13C nuclear magnetic resonance (NMR) 
1D/2D and mass spectrometry (MS) combined with chemical treatments of the sample, can 
provide further clues about the kind, sequence and ratios of the monosaccharides present, 
the type of bonds (α- or β-) between individual sugars, the branching points and reducing 
and non-reducing ends, and its molecular weight.  
The experimental procedures that are most frequently used in the process of solving the 
polysaccharide structure are: 
1. Sample purification 
A solid, crude, non-homogenous, polysaccharide must be solubilized in an appropriate 
solvent (water) or, in the case of insoluble polysaccharides, it must be subjected to chemical 
or enzymatic degradation (with minimal damage to the original structure) to reduce the 
polymer size which then allows the sample to become soluble. Sample solubilization makes 
the use of various chromatographic techniques (i.e., ion exchange chromatography, size 
exclusion chromatography, affinity-chromatography, sorbent-liquid chromatography) for 
sample fractionation and purification, possible.  
2. Composition analysis 
Complete acid hydrolysis is used to cleave all glycosidic bonds in the polysaccharide and to 
release D-glucose as a single product (in the case of glucans), which is then identified by 
comparison to a D-glucose standard. 
3. Methylation linkage analysis 
All of the polysaccharide hydroxyl (OH) groups are methylated using an excess of 
methylation reagent (dimsyl sodium followed by methyl iodide). Obtained this way, the 
fully O-methylated derivative is then subjected to acidic hydrolysis of all glycosidic 
linkages. The released O-methylated derivatives of D-glucose: 2, 3, 4, 6-O-tetramethyl-D-
glucose; 2, 3, 4-O-trimethyl-D-glucose; 2, 4-O-dimethyl-D-glucose are identified and 
quantified using HPLC/MS and appropriate standards. In the case of pentasaccharide (Fig.1) 
the ratios of the methylation products would be 2:2:1. 
4. Spectroscopy 
Finally, 1H and 13C NMR and M S are used to establish the sequence of glucopyranose rings, 
the position of branching points, the number of non-reducing ends and the nature of 
glycosidic bonds (α or β). If the polysaccharide contains repeating sequences, their ratios can 
be also established. 
5. Enzymatic action 
Glycosidases and lectins of known specificity are applied to confirm glucose oligosaccharide 
structures, from which the complete polysaccharide architecture can be deduced. 
The Complex Carbohydrates Research Center located at The University of Georgia 
(http://www.ccrc.uga.edu) offers services covering all of the aspects of the polysaccharide 
structural assignments. 
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2. Fungal and yeast cell wall, D-glucose homo- and hetero-
polysaccharides 
Fungi constitute an independent evolutionary group of eukaryotic organisms equal in rank 
to that of plants or animals. They can excrete hydrolytic enzymes that break down 
biopolymers (polysaccharides and proteins) of plant or animal origin and use sugars and/or 
amino acids for their nutrition. Yeast is a single-cell fungus and the Saccharomyces cerevisiae 
species (baker’s or brewer’s yeast) has been utilized by people from early human civilization 
in food and beverage preparation. Mushrooms are fungal fruiting bodies; edible mushrooms 
are taste improving, “healthy” food ingredients that are very popular on European and 
Asian menus. Extracts and dried powders made by processing “medicinal mushrooms” are 
important ingredients of traditional Eastern medicinal remedies.  
Fungal cell walls are made of polysaccharides. Chitin, a homopolymer of (1→4)-β-D-N-
acetylglucosamine and various glucans (homopolymers of D-glucose, with α- or β- 
glycosidyl linkages between C-1 and C-2, C-3, C-4 and C-6 of glucopyranose rings) are the 
most frequently found building blocks used by nature in construction of the cell wall that 
separates the fungus from the environment. In yeast, α- and β-glucans and α-mannan are 
the major polysaccharides (chitin is present at 1-2%) that are utilized in cell wall 
construction. Their ratio changes with yeast strain and growth stage and is dependent upon 
growth conditions including oxygen and nutrient availability and the temperature and pH 
of the medium (Stewart & Russell, 1998). Table 1 shows the average abundance of yeast cell 
wall components. 
 
Component Cell wall mass 
(%, dry weight) 
(1→3)-β-D-glucan 50-55 
(1→6)-β-D-glucan 5-10 
(1→4)-α-(1→3)-β-D-glucan 3-7* 
Mannoprotein complex 35-40 
Chitin 2 
Mannan structure can be represented by the following formula: poly-(1→2) (1→3) (1→6)-α-D-mannopyranose. This 
polysaccharide is built out of a long backbone chain of (1→6)-α-D-mannopyranose rings with short mannopyranose 
chains (one to four rings long, connected through (1→2) and (1→3)-α-glucoside bonds (Ballou, 1980). 
Table 1. The cell wall components of Saccharomyces cerevisiae (Klis et al. 2002; Kath & Kulicke, 1999; 
Lessage & Bussey, 2006; Kwiatkowski et al., 2009) 
The yeast cell wall forms a border that defines the yeast cell’s dimensions and separates its 
organelles from the negative influences of the environment. The individual constituents of 
the cell wall connect to each other by covalent bonds forming a single supra-molecular 
biopolymer. To find the nature of these connections, as well as the individual 
polysaccharides structures, all of the architectural elements must be dissected, solubilized, 
purified and analyzed. In this process it is almost impossible not to damage particular 
structural elements and to afterwards distinguish between the original components of the 
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cell wall and soluble polysaccharides that could be present in the cytoplasm or might be 
trapped (physically absorbed) within cell wall. More than 50 years of research were required 
to establish the structure of the major, high molecular weight yeast homo-polysaccharides 
(Bacon & Farmer, 1969; Aimaniada et al., 2009).  
The (1→3)-β-D-glucan and (1→6)-β-D-glucan form a single structure in which the (1→3)-β-
D-glucan forms the backbone chain with (1→6)-β-D-glucan branches that are attached to 
branching glucopyranose rings at C-6 (Lessage & Bussey, 2006). The (1→3)-β-D-glucan 
chains form triple helix tridimensional structures with spring-like mechanical properties, 
responsible for the yeast cell wall’s strength (Klis et al., 2002) and its ability to absorb toxins 
(Yiannikouris et al., 2004). The (1→6)-β-D-glucan is a linker between (1→3)-β-D-glucan, 
chitin and mannoproteins (Kaptein et al., 1999; Kollar et al., 1997) that stabilizes the whole 
structure and is the main cause of yeast cell wall insolubility. The properties and role of a 
mixed (1→4)-α-(1→3)-β-D-glucan from yeast cells will be discussed in section 3 of this chapter. 
Mannoproteins are mostly located on the outside surface of the cell wall (Osumi, 1998). They 
play a sensory function for nutrients and chemical and bacterial/viral toxins, actively 
participate in the transport of nutrients and metabolites through the cell wall, and also 
participate in mating (Klis et al., 2002; Stewart & Russell, 1998). Some cell wall enzymes such 
as glucanase, mannanase, invertase, alkaline phosphatase and lipase are mannoproteins 
(Stewart & Russell, 1998) that hydrolyze nutrients and participate in the reconstruction of cell 
polysaccharides during cell growth and budding. Cell wall mannans are connected with cell 
wall glucans via covalent bonds, but they can be released under action of an alkaline medium 
in which they are perfectly soluble. The process of separating yeast cell wall glucans (which 
stay as an insoluble fraction) from yeast mannans is used on an industrial scale (Sedmak, 
2006). The soluble, mannan-rich fraction, can be added back to the cell wall which contains 
only 10-17% mannan by weight, to increase the content of mannan to 30% by weight. Such a 
product is sold by Alltech Inc. under the name of ActigenTM to the animal nutrition industry.  
The small fraction of chitin present in yeast cell wall is primarily located in the scar rings 
around buds in budding yeast and secures closure of the gaps in the mother cell and the 
departing daughter cell (Lessage & Bussey, 2006; Stewart & Russell, 1998). 
3. α-D-glucans from baker’s yeast (Saccharomyces cerevisiae) 
The role of (1→3)-β-D-glucan in the maintenance of yeast cell wall shape and rigidity 
(Lessage & Bussey, 2006; Klis, et al. 2006) and (1→6)-β-D–glucan as a polysaccharide that 
links together all of the cell wall polysaccharides (Aimaniada et al., 2009; Kollar et al., 1997) 
is well documented and has been reviewed by Lessage & Bussey (2006) and Klis et al. (2002). 
The presence of starch-like, “alkali-soluble glycogen, “an “energy storage polysaccharide” in 
cell cytosol, and “difficult to dissolve acid-soluble,” glycogen like (1→4)-α-D-glucan in the 
cell walls of Saccharomyces cerevisiae grown aerobically, was frequently mentioned in early 
yeast literature (Grba et al., 1976). The two forms of glycogen synthetase have also been 
identified (Rothman-Denes & Cabib, 1970; Lille & Pringle, 1980) but the yeast literature is 
still treating the “difficult to dissolve” α-glucan as physically adsorbed cytosol glycogen, 
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trapped within yeast cell wall, and not as an independent component attached by a covalent 
bond to the other cell wall polysaccharides. In 1973, Manners et al. reported: “β-1, 6-glucan 
purified after acid extraction had to be exhaustively treated with α-amylase and still showed 
the presence of glucose and maltose in paper chromatographic analysis, along with 
gentiobiose and higher gentiooligosaccharides,” which are (1→4)-α-D-glucan 
oligosaccharides formed during enzymatic hydrolysis of the mixed α, β-glucan from the 
yeast cell wall.  
The α-glucan content in the yeast cell wall is reported to vary from as little as 1% (Lille & 
Pringle, 1980) to as much as 29% (Sedmak, 2006) of the dry weight, depending upon the 
nutritional status of the cells, the method of isolation, the method of analysis and the phase 
of growth during which the cells were harvested (Lille & Pringle, 1980). Spectrophotometric 
analysis of soluble glycogen can be run directly on a water extract, and if properly done, 
yields reliable results (Quain, 1981). Quantitative analysis of “insoluble” glycogen requires 
additional, enzymatic release of glucose from its mixed polysaccharide with β-glucan (see, 
http://www.megazyme.com). The industrially produced brewer’s yeast described in 
Sedmak’s US patent application (Sedmak, 2006) contains glucans (α + β) at 28.9% dry 
weight, which includes 12.4% α-glucan. Hydrolysis of these water-insoluble cells with 
alkaline protease solubilizes the mannoprotein complex and yields water-insoluble cell wall 
polysaccharides (including α-glucan) that contain 54.5% dry weight of glucans with more 
than half of the total weight (29.2%) as α-glucan. 
Arvindekar and Patil (2002) proposed an explanation for the presence of α-glucan in the 
insoluble fraction from yeast cell walls, which has been described by others as “difficult to 
wash away” yeast glycogen (Gunia-Smith et al., 1977; Manners & Fleet, 1976). They found 
that the ratio of “soluble” to “insoluble” glycogen in different strains of Saccharomyces 
cerevisiae is in the range of 1:2.5–1:3. When the insoluble fraction was digested with purified 
lyticase, which possessed only (1→3)-β-D–glucan hydrolyzing activity and no (1→6)-β-D–
glucan or (1→4)-α-D-glucan hydrolyzing activities, all of the material dissolved. The affinity 
chromatography of the solution on a Concanavalin A (ConA) column retained a fraction 
that contained mixed (1→4)-α-(1→6)-β-D–glucan polysaccharide. The eluent contained 
exclusively (1→3)-β-D–glucan oligosaccharides. When the (1→4)-α-D-glucan-rich fraction 
was released from its binding with ConA and treated with amyloglucosidase followed by 
dialysis to remove glucose, subjecting the resulting solution to affinity chromatography on a 
ConA column showed none of the material was retained. The material recovered from the 
solution was then proved to be pure (1→6)-β-D–glucan. These simple experiments showed 
that the “insoluble glycogen” from yeast cell wall is a mixed glucan in which (1→4)-α-D-
glucan is connected to (1→3)-β-D–glucan through a (1→6)-β-D–glucan link. The structure of 
this mixed yeast cell wall (1→4)-α-(1→6)-β-(1→3)-β-D-glucan was confirmed by our 1H 
NMR study (Kwiatkowski et al., 2009) and methylation analysis done at CCRC.  
We used yeast cell wall α-glucan (prepared in our laboratory) in the development of the 
enzyme linked immunosorbent assay (ELISA) for yeast cell wall quantitative analysis in a 
complex polysaccharide matrix (Moran et al., 2011). The antigen was prepared in two stages. 
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At first a sample of cell wall (1→4)-α-D-glucan (fraction 50-100 kDa separated with the help 
of an ultra centrifugal filter (Aldrich Inc.) was oxidized mostly at the C-6 carbons using the 
Albright-Goldman oxidation reagent (Albright & Goldman, 1967; Zekovic et al., 2006) which 
converted the –CH2OH groups into aldehyde groups –CH=O in glucopyranose rings. The 
reaction produced a highly cross-linked polymer, with internal acetal bonds, but still well 
soluble in DMSO (dimethyl sulfoxide) and water, which was coupled to a bovine serum 
albumin (BSA), yielding the antigen (glucan-BSA conjugate). To restore the original α-
glucan structure, but with –CH2–NH-BSA groups instead of –CH2-OH groups at the 
glucan’s C-6 carbon, the conjugate C-6 imino (-CH=N-BSA) groups were reduced with 
sodium cyanoborohydride (Baxter & Reitz, 2002). Sodium dodecyl sulfate (SDS) 
polyacrylamide gel electrophoresis (PAGE) of the conjugate indicated the presence of 
significant quantities of free BSA (line at 66 kDa) together with the glucan-BSA conjugate of 
molecular size between 100 and 175 kDa. To remove the excess BSA, the concentrated 
solution of the conjugate was washed with water of pH 7.0, 8.5 and 4.5 using an ultra 
centrifugal filter with the 50-kDa membrane. This “purified” conjugate was used then in 
rabbit immunization. We found that the rabbit polyclonal antibodies were very sensitive to 
yeast cell wall α-glucan, but (as expected) they were also cross-reactive with BSA. To delete 
this activity we synthesized the BSA-coated affinity phase (Moran et al., 2011) and removed 
antibodies specific to BSA from the crude fraction of polyclonal rabbit anti-α-glucan 
antibodies. We also found that antibodies grown against this α-glucan polysaccharide did 
not recognize any commercially available starch or glycogen samples, including yeast 
glycogen. Such specificity confirms structural differences between the cell wall and the 
cytosol α-glucans from Saccharomyces cerevisiae. Because of the high specificity and very low 
cross reactivity of the “purified” rabbit antibodies with soy proteins and corn carbohydrates, 
the ELISA cell wall assay detects and quantifies samples of yeast cell wall down to 50 g/ton 
of feed (Moran et al., 2011). A similar assay was used for quantification of α-D-glucan-
protein complex in mushrooms with immunomodulatory activity (Hirotaka et al., 2007).  
What is the role of this polysaccharide in yeast cell life? Some remarks in the literature point 
to its role in yeast flocculation (Patel & Ingledew, 1975), acting as part of a possible killer 
toxin receptor (Hutchkins & Bussey, 1983) and as being sensitive to environmental 
conditions and changes in medium (Slaughter & Nomura, 1992; Dake et al., 2010; Jadhav et 
al., 2008). The cell wall bound α-glucan from fission yeast Schizosaccharomyces pombe has 
been studied in detail (Villar-Tajadura et al., 2008; Vos et al., 2007 ; Garcia et al., 2006; Grün 
et al., 2005), and systematic identification of the genes affecting glycogen storage in the yeast 
Saccharomyces cerevisiae was attempted (Wilson et al., 2002). Unfortunately, the presence of 
the two different pools of glycogen was not addressed. One of the possible functions of 
bound α-glucan might be the temporary formation of mixed α, β-glucan oligosaccharides 
that become soluble in cytoplasm and can be transported inside the cell wall where the β-
glucan fragment is used in the construction of insoluble yeast cell wall β-glucan 
polysaccharide.   
Is it possible that α-glucan polysaccharides from yeast or mushrooms can have medicinal 
properties? There is no literature concerning the medicinal properties of α-glucan as a 
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separate fraction of the yeast cell wall, which is a consequence of acknowledging it as part of 
an energy storage cellular polysaccharide-yeast glycogen. Bioactive components containing 
α-glucan, mixed α, β-glucan or α-glucan-protein complexes are known to be present in 
extracts from the fruiting bodies of edible medicinal-mushrooms. Like in the case of many 
other traditional herbal remedies, it is difficult to separate the single bioactive component’s 
(α-glucan) bioactivity from the activities of the other components of the extract, and in some 
cases, early assignments were incorrect. 
Mushrooms with medicinal activities that contain extractable α-glucan in their fruiting 
bodies, belong to one of two phyla: Ascomycota or Basidiomycota. Hot-water extracts from 
Peziza vesiculosa (Ohno et al., 1985; Suzuki et al., 1982) and Cordyceps chinensis (Yan et al., 
2011; Holliday & Cleaver, 2008; Khan et al., 2010; Liu et al., 2006; Kiho et al., 1993; Kiho et al., 
1996; Li et al., 2006), which are both Ascomycota, have been shown to have antitumor and 
anti-diabetic activities. The linear α-(1→4)-D-glucan is less active than α-(1→4) (1→6)-D-
glucan with 1 to 6 branches on the backbone 1→4 chain with a ratio of 1:8. The biological 
activity of glycogen-like polysaccharides was found to be molecular-size dependent with 
smaller ~9.5 kDa molecules being active, whereas 14-24 kDa molecules were not (Kakutani 
et al., 2007).  
More is known about edible mushrooms belonging to Basidiomycota which contain both: α- 
and β-glucans in their fruiting bodies (Rop et al., 2009). Hot-water extracts from Peziza 
vesiculosa show antitumor activity (Ohno et al., 1985; Suzuki et al., 1982) and extracts from 
Grifola frondosa (Maitake) show glucose suppression (Tanaka et al., 2011) and antidiabetic 
(Lei et al., 2007) activities. Extracts (Shida & Matsuda, 1974) from Lentinus edodes (Shiitake) 
stimulate the immune system (Shah et al., 2011; Terakawa et al., 2008) and possess 
antibacterial, antiviral (Mach et al., 2008) and anticancer properties (Shida & Matsuda, 1974; 
Hyodo et al., 2005; Shah et al., 2011). Extracts from Tricholoma matsutake (Matsutake) show 
antitumor (Ebina et al., 2002) and immunomodulatory (Hirotaka et al., 2007; Hirotaka et al., 
2005) activities. Extracts (Smiderle et al., 2010) from Agaricus bisporus (Portobello) inhibit 
breast cancer cell proliferation (Grube et al., 2001) and stimulate the immune system (Ren et 
al., 2008; Koppada et al., 2009). A glycogen-like polysaccharide from Portobello mushrooms 
potently activated macrophages, stimulating TNF-α production and phagocytosis of 
RAW264.7 cells (Kojima et al., 2010). Extracts from Pleurotus ostreatus (Oyster mushroom) 
show antiproliferative and proapoptotic activities on colon cancer cells (Lavi et al., 2006). 
Pholiota nameko (Butterscotch mushroom), which has been in use as a major component of 
miso soup in Japan, shows antinflammatory activity (Li et al., 2008). In Asian and European 
culinary traditions, meals containing these mushrooms are believed to be healthy and to 
heal a variety of ailments. 
Whether α-glucan from yeast cell walls can contribute to the known medicinal activities of 
various extracts from whole yeast is still an open question. Newly developed, simple 
methods for producing large quantities of this material (Kwiatkowski et al., 2009; Moran et 
al., 2011) should stimulate new research in this area. 
The abundant literature regarding bioactivity of the whole yeast cell wall and its extracts 
rich in α-mannoprotein or β-glucan, will be discussed in sections 4, 5 and 6 of this chapter. 
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4. Baker’s yeast cell wall β-D-glucan/α-mannoprotein complex 
Yeast cell wall biogenesis was studied by Smits (Smits et al, 2001) who found that “The yeast 
cell wall forms a border that defines the yeast cell’s dimensions and separates its organelles 
from the negative impact of the environment. All of the individual constituents of a yeast 
cell wall connect to each other by covalent bonds forming a single supra-molecular 
biopolymer”. The (1→3) (1→6)-β-D-glucan and the (1→2) (1→3) (1→6)-α-D-mannan/protein 
complexes (Vinogradov et al., 1998) are the major components of this supra-molecular 
biopolymer (Lessage & Bussey, 2006; Kath & Kulicke, 1999). They connect to each other by a 
covalent bond the nature of which is still under investigation (Kaptein et al., 1999; Kollar et 
al., 1997). In the process of yeast cell wall isolation the cell wall is first cracked open, with 
the help of physical, chemical and/or enzymatic treatments (Kath & Kulicke, 1999) and then 
separated from the soluble yeast cell components by centrifugation (Sedmak, 2006; Jamas et 
al., 1998). The concentrated yeast cell wall solids containing ~30% dry weight material are 
then spray-dried. The resulting product is a fine powder with a light tan color. The cell wall 
polysaccharides can be separated from each other by alkaline extraction, which solubilizes 
the α-mannoprotein fraction and leaves β-glucan particles in suspension. The β-glucan 
particulate can be separated from the soluble α-mannoprotein fraction by centrifugation and 
spray-dried to yield light, yellow colored, fine powder, free of any smell or taste, containing 
~65% β-glucan. The α-mannoprotein solution can then be concentrated by using membrane 
ultrafiltration and spray-dried to produce a light brown, “mannan rich fraction” with ~40% 
by weight of α-mannan. Yeast cell walls as well as both fractions of polysaccharides are 
produced on a large scale and have practical applications as animal feed nutritional 
supplements. Furthermore, this yeast cell wall preparation, sold by Alltech Inc. under the 
name of Bio-Mos®, was proved (in more than 600 feeding trials) to have a positive impact 
on the immune system of livestock (Baurhoo et al., 2009; Yang et al., 2008; Rosen et al., 2007; 
Jacques & Newman, 1994; Morrison et al., 2010) fish (Dimitroglu et al., 2009), and 
companion animals (Swanson et al., 2002) when added to feed at the rate of 0.5-2.0 kg/ton. 
Bio-Mos® contains ~17% of α-mannan, which is possibly its bioactive component. An 
improved form of Bio-Mos® is marketed by Alltech Inc. under the name ActigenTM. This 
improved product contains 30% α-mannan and is manufactured, by mixing yeast cell wall 
with a mannan-rich fraction. ActigenTM product is four times more active than Bio-Mos® 
(~13% of it is soluble and therefore, better available to interaction with microbes and animal 
gut) and its application rate of 250-500 g/ton approaches that of antibiotics. Alpha-D-
mannans have a “brush like” structure built out of α-(1→2)- and α-(1→3)-D-mannopyranose 
branches, 1 to 5 rings long (brush hair), which are attached to a ~120-ring-long α-(1→6)-D-
mannopyranose chain, the brush handle (Vinogradov et al., 1998). This structure creates a 
specific combination of various functionalities that also involve protein conjugates. It can fit 
with various receptors present on the walls of animal digestive tracts (Mansour & Levitz, 
2003) and with the receptors on the membranes of pathogenic bacteria (Wellens et al., 2008). 
Alpha-D-mannan/protein-conjugates are involved in interactions with animal immune 
systems and as a result enhance immune system activity (Wismar et al., 2010) and contribute 
to animal antioxidant and antimutagenic defenses (Krizkova et al., 2006). Immune system 
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strength, blockage of bacterial adhesion to the gut and modification of the gut structure 
contributes to improved survival and better growth in young animals. The second major 
yeast cell wall polysaccharide, (1→3)(1→6)-β-D-glucan, might also contribute to yeast cell 
wall biological properties (section 5 of this chapter), but its major role in animal nutrition is 
its ability to bind mycotoxins and detoxify animal feed. The (1→3)(1→6)-β-D-glucan is a 
part of the cell wall’s ”triple helix tridimensional structure, with spring-like mechanical 
properties, responsible for yeast cell wall strength and ability to absorb toxins” (Yannikouris 
et al., 2004) (see section 2, this chapter). Toxins occurring in plant-derived animal feed 
belong to one of two groups. Mycotoxins (the first group) are the by-products of the 
secondary metabolism of pathogenic fungi (Bennet & Klich, 2003), whereas chemical toxins 
(the second group) are incorporated into plant tissue as a result of plants metabolizing 
agrochemicals from the soil or water used for irrigation (McLean & Bledsoe, 1992). Some of 
the most problematic mycotoxins in causing human or animal diseases (i.e., aflatoxin, 
citrinin, ergot alkaloids, fumonisins, ochratoxin A, patulin, trichothecenes and zeralenone; 
Smith et al., 1995) can be absorbed by yeast cell wall β-glucans (Yiannikouris et al., 2004; 
Yannikouris et al., 2006). A mixture of cell wall β-glucan with clay (bentonite) sold as 
Mycosorb® by Alltech Inc. offers a spectrum of mycotoxin absorption superior to that of 
yeast cell wall glucans alone and also absorbs heavy metals (Brady et al., 1994). As in the 
case of Bio-Mos® a multitude of feeding trials have demonstrated the efficacy of Mycosorb® 
as an animal feed detoxifier using companion animals (Leung et al., 2006), horses (Raymond 
et al., 2003), pigs (Kogan & Kohler, 2007) and poultry (Dvorska et al., 2003; Karaman et al., 
2005; Valarezo et al., 1998). 
The whole yeast Saccharomyces cerevisiae grown in a medium containing inorganic selenium 
(Demirici & Pometto, 1999; Demirici et al., 1999; Mapelli et al., 2011) is used to produce yet 
another yeast-based human/animal nutritional supplement SelPlex® (Alltech Inc.). To 
maintain healthy metabolism, the human body requires 17 µg of selenium a day. Dietary 
selenium is used to synthesize selenocysteine (in liver) and is then incorporated into more 
than 25 Se-containing enzymes that play important roles in body’s defense against free 
radical species (Tapiero et al., (2003) and in many other cellular processes including the 
generation of energy in mitochondria (Rayman, 2000). Because yeast does not possess genes 
that control selenium metabolism (Rodrigo, 2002), selenium, which has chemical properties 
extremely similar to sulfur, is metabolized in the same manner as sulfur and randomly 
incorporated into yeast cytosol, small-molecules like Se-glutathione, Se-adenosylhomo-
cysteine (Uden et al. 2003) and proteins as Se-methionine (Tastet et al., 2008). Unlike yeast, 
mushrooms can metabolize selenium and can accumulate large quantities of it (Turlo et al., 
2007) in the form of selenomethionine and selenocysteine. Animal feeding studies clearly 
showed that SelPlex® is not just a selenium source, but it also carries a variety of beneficial 
effects such as increased animal fertility (Rayman, 2000) or improved animal immune 
system activity (Rayman, 2000). Additionally, feeding SelPlex® to mice has been shown to 
delay the development of brain tumors from malignant human cancer cells implanted in 
mice brains (Toborek, 2011) and can significantly limit the deposition of Aβ amyloid plaques 
in APP/PS1 mouse brains that carry human Alzheimer’s disease genes (Lovell et al., 2009). 
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Only some of these effects can be promoted by regular yeast cell wall preparations. 
However separating the bioactivities caused by the selenomethionine-containing yeast 
proteins from the activity caused by the polysaccharide parts of selenized yeast cell walls is 
difficult. Comparison of genomic activity in tissues taken from animals fed with SelPlex® to 
those fed with Bio-Mos® spiked with selenomethionine indicates very large differences in 
the regulation of multiple groups of genes for both treatments (Kwiatkowski et al., 2011), 
which may indicate that the bioactivity of Sel-Plex® involves cooperation between the 
selenoprotein and the polysaccharide components of selenized yeast cell walls.  
Indeed, selected extracts from selenized yeast/yeast cell walls (Kwiatkowski et al., 2011) 
show potential as future, possible treatments of diseases such as type 2 diabetes, cancer and 
Alzheimer’s. 
5. β-(1→3)(1→6)-D-glucan as valuable by product from yeast 
fermentation 
The commercial source from which the bulk yeast cell wall polysaccharides (including β-
glucan) are produced uses the same strains of yeast as are used in fuel alcohol production. 
Le Saffre/ADM, Lallemand, Enzyme Development (New York) and DSM Life Sciences 
(Delft) are the largest suppliers of yeast for fuel ethanol producers in the United States and 
the European Union. Major factors that affect yeast cell wall composition include yeast 
strain (Hahn-Hagerdal et al., 2005), growth conditions (growth medium, temperature, 
osmotic pressure, toxic metabolites) and the time of harvesting (Aguilar-Uscanaga & 
Francois, 2003; Klis et al., 2002; Klis et al., 2006). Fuel alcohol fermentation is a high stress 
process (Devantier et al., 2005) and the cell walls of the yeast collected as its byproduct 
contain a high amount of β-glucans (Basso et al., 2008; Knauf & Kraus, 2006; Jones & 
Ingledew, 1994). In general, yeast strains of Saccharomyces cerevisiae that are used in baking 
(baker’s yeast) have a higher β-glucan-to-α-mannan ratio than those that are used for 
alcohol fermentation (brewer’s yeast), therefore it is advantageous to use pure baker’s yeast 
for producing high quality (1→3)(1→6)-β-D-glucan for medicinal applications (Kim et al., 
2007). The process of separating various yeast components has been heavily patented. 
However, the differences in the technologies are minor and in principle do not differ from 
the methodology described by Manners and Fleet (1976). The process starts from autolysing 
yeast cells at a temperature between 45oC and 65oC at slightly acidic pH, to release yeast cell 
walls that are insoluble and denser than the cytoplasmic contents and can be separated by 
centrifugation (Wheatcroft et al., 2002). These steps can be followed by incubating the yeast 
cell walls with alkaline protease at a pH of 9 to 10 to solubilize mannans and leave behind 
insoluble β-glucan (Zapata et al, 2008), which can then be physically separated from the 
liquid fraction by centrifugation and subsequent washing (Sedmak, 2006). Additional 
enzymes, like glucoamylase and lipase, can be used to hydrolyze α-glucan from α β-glucan, 
which is still present in the cell wall material and to solubilize the residue lipids from cell 
membranes. The final step of β-glucan production is a spray-drying that produces a white-
to-maroon colored powder that does not carry any taste or aroma and is useful for feed and 
food applications. Further alkaline and acidic treatments of the food-grade β-glucan (Kelly, 
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2001) yields high purity (98.5% β-glucan, <0.1% mannan, 0.4% α-glucan, 0.3% protein, 0.2% 
chitin) microparticulate β-glucan with reduced molecular weight (from ~1-3 MDa to ~150 
kDa) that is much more easily absorbed by the digestive tract and shows improved activity 
compared with food-grade products containing only ~65% β-glucan. Even further 
hydrolysis produces soluble yeast β-glucan (Jamas et al., 1998; Lee et al., 2001) that still 
retains most of the particular β-glucan bioactivities (Janusz et al., 1986; Wakshull et al., 
1999).  
Yeast Saccharomyces cerevisiae, its cell wall and products of its fractionation are generally 
recognized as safe (GRAS) by the US Food and Drug Administration (FDA, 1997), and they 
can be legally used as food ingredients but not as food additives. The European Food Safety 
Authority (EFSA) issued an opinion that yeast β-glucans are a “safe food ingredient” (EFSA, 
2011) that can be used as a “food supplement” up to 375 mg/day and in foods for “particular 
nutritional uses” at dose levels up to 600 mg/day. (The uses of yeast cell wall as an animal 
feed ingredient were discussed in section 4 of this chapter).  
Food-grade yeast β-glucans such as BetaRight® and WGP® (Biothera, Inc.) are used as 
ingredients in baked foods, beverages, ceral, yogurt, fruit juices, chocolate and as food 
thickeners in salad dressings, ice cream, mayonnaise, sauces and cheese. The majority of 
these applications have been patented (Zechner-Krpan et al., 2009; Thammakiti et al., 2004) 
and a critical review of 300 patented applications is available (Laroche & Michaud, 2007). 
Yeast β-glucans improve food rheological properties, gelling, water and oil-holding 
properties, without impacting its taste or odor (Petravic-Tominac et al., 2011). Beta-glucans 
also add health benefits (Laroche & Michaud, 2007) like antioxidative, bacteriostatic and 
immunostimmulating activities. Cosmetic products used in skin treatment contain yeast β-
glucans as moisturizing and moisture-retaining components that also provide a proper 
moistening feeling. Because of its emulsion-stabilizing effects, pleasant texture and 
antioxidant activity yeast β-glucans can prevent skin injuries caused by solar radiation and 
therefore are used in sun-screens, oils and gels (Michiko & Yutaka, 2007). Deodorants 
containing yeast β-glucans have proved to be useful in oral preparations, mouthwashes and 
diapers (Michiko et al., 2005). Acid-treated cell walls (AYC) can be used as new binders in 
pharmaceutical formulations and, when mixed with traditional fillers like 
hydroxypropylcellulose or polyvinylpyrrolidone, yield harder pills with very short (~2 min) 
dissolution times (Yusa et al., 2002). Its adhesive and biological properties can be also 
utilized in producing coating for surgical instruments (Klein, 2003) and in the manufacture 
of packaging for the food industry (Cope, 1987). Its antibacterial and antiviral properties 
have found application in the control of plant pests (Kitagawa, 2007) and viral invasions 
(Slovakova et al., 1997).  
6. Medicinal application of native and chemically modified forms of  
β-(1→ 6)(1→3)-D-glucan 
Approximately 2000 research and review papers covering β-(1→6)(1→3)-D-glucan 
bioactivity and its medicinal applications have been published since the 1960’s, and the 
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majority of the literature has been reviewed (Bohn & BeMiller, 1995; Kogan, 2000; Zekovic et 
al., 2005; Vetvicka, 2011; http://www.betaglucan.org; and for patented applications see 
Laroche & Michaud, 2007). Many early assumptions have been confirmed by more rigorous 
studies, and many others have been disproven. Many of the studies that initially showed 
promise utilized poorly purified and not sufficiently standardized samples of yeast cell wall 
glucan (Jaehrig et al., 2007; Vetvicka & Vetvickova, 2007). Highly purified, insoluble, whole-
glucan particles (WGP) with the size 2-4 µm (Yan et al., 2005), or soluble, yeast poly-(1→6)-
β-D-glucopyranosyl-(1→3)-β-D-glucopyranose (PGG) with molecular weight ~150 kDa 
(Gawronski et al., 1999) is presently used in animal and human studies. Glucan samples 
used in earlier studies could contain significant quantities of (also) bioactive impurities like 
yeast mannoproteins or α-glucans. The existence of a correlation between the β-(1→6)(1→3)-
D-glucan structure and its bioactivity is well established having been confirmed by multiple 
animal and human studies (Novak & Vetvicka, 2009). The WGP-glucan fate after oral 
administration and PGG-glucan after intravenous administration has been studied in 
animals (Vetvicka & Vetvickova, 2008). Mammalian cells lack β-glucan, which is present in 
the cell wall of many infectious microbes. Thus, mammalian macrophages, which are 
present “on guard” in the cells lining the digestive track, recognize and bind purified β-
glucan, but not the whole yeast cells (which have mannoproteins on the cell surface), via the 
dectin-1 receptor, which is a glucan-sensing receptor expressed on dectin a transmembrane 
protein. The macrophages transport β-glucan molecules to the spleen, bone marrow and 
lymph nodes where they are disintegrated into smaller, soluble, β-glucan oligosaccharides 
that are released back into the bloodstream. The circulating monocytes, macrophages, 
neutrophils, natural killer and dendritic cells (Chan et al., 2009) which possesses β-glucan 
recognizing receptors, including: toll like receptor 2 (TLR-2, Underhill et al., 1999), dectin-1 
(Brown et al., 2007), complement receptor 3 (CR-3) (Ross et al., 1987) and lactosyl ceramide 
receptor, bind to the β-glucan molecules triggering the non-specific-innate immune 
response, including phagocytosis and production of proinflammatory factors (Qi et al., 
2011). This mechanism leads to the elimination of infectious agents (Chan et al., 2009). 
Cancer cells are recognized by the host immune system, but antibody response is too weak 
to destroy them. When humanized, anti-cancer monoclonal antibodies are used in cancer 
therapy the treatments are not uniformly effective. Combined antitumor monoclonal 
antibodies (mAb’s) and β-glucan therapy yields much better results with fewer adverse side 
effects (Salvador et al., 2008; Liu et al., 2009). The mechanism of action is only partially 
understood with neutrophils and macrophages playing a role in the process of killing cancer 
cells (Liu et al., 2009). Strengthening immunity to various diseases (Hofer & Pospisil, 2011) 
and combating those that are already active in humans and animals are the main 
applications of yeast β-glucan. In Eastern culinary tradition, eating mushrooms (which 
contain large quantities of soluble β-glucan in their fruiting bodies) has long been 
recognized as healthy, and four pharmaceutical preparations, based on mushroom extracts, 
have been registered as drugs in Japan (Hyodo et al., 2005). In the Western world several 
clinical trials (Babineu et al., 1994; Weitberg, 2008; Spruijt et al., 2010) proved the beneficial 
properties of WGP and PGG glucans, which are still waiting to be registered as drugs 
(Vetvicka, 2011; Lehtovaara & Gu, 2011). The following therapeutic activities of yeast β-
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glucan are well-established in treating the following conditions: post-surgical infections, 
hospital pneumonia, acute renal failure (Koc et al., 2011), pressure ulcers (bed sores), wound 
healing (surgical and as result of injury, Spruijt et al., 2010) and burns caused by heat, UV or 
X-ray radiation. As an adjuvant yeast β-glucans alleviate stress and improves the mAb’s 
plus PGG anticancer treatment for breast, colorectal, colon, leukemia, lung, ovarian and skin 
cancers, chemotherapy and radiotherapy; antireumatic drug therapy (Sener et al., 2006), and 
antifungal therapies. They stimulate bone marrow healing and bone repair (due to injuries), 
which increases red blood cell count and neutrophil production. Many of these activities 
were studied in the 1990s and 2000s and have been reviewed. Studies since 2010 have been 
referred to herein. 
Some of the negative side effects that have been observed in response to prolonged or large 
doses of β-glucan preparations are the consequences of their mode of action as well as their 
physical and chemical properties. Their therapeutic activity is based upon immune system 
mobilization and the production of monocytes, macrophages, neutrophils, natural killer and 
dendritic cells which fight and destroy pathogens. However, prolonged pro-inflammatory 
changes in cells can cause the development of autoimmune diseases. The human body is 
missing enzymes that can hydrolyze β-glucan polysaccharides and for their degradation 
uses less efficient oxidative pathways. This insufficiency extends the cellular half-life of 
WGP and PPG glucans and can lead to the formation of granulomas in the liver, causing 
inflammation that can result in liver cirrhosis. Therefore the use of soluble and relatively 
low molecular weight PGG glucan is recommended. The well documented β-glucan abilities 
to lower blood sugar and blood pressure justify further study aimed at producing a glucan 
material with molecular weight lower than that of PGG glucan to preclude accumulation in 
granulomas, when used as a long-term food additive. The next stage of development of less 
toxic, soluble β-glucan preparations should include its size fractionation to produce more 
standardized material for medicinal applications. The majority of in vivo studies on β-glucan 
medicinal applications were done using rodent models, therefore it is easy to foresee 
veterinary applications of this food/feed ingredient to improve immune systems, facilitate 
burn and wound healing, stimulate post-trauma bone repair and help fight cancers. 
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